Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
1.
World J Clin Cases ; 3(11): 935-41, 2015 Nov 16.
Artigo em Inglês | MEDLINE | ID: mdl-26601096

RESUMO

AIM: To develop a framework for the clinical and health economic assessment for management of Clostridium difficile infection (CDI). METHODS: CDI has vast economic consequences emphasizing the need for innovative and cost effective solutions, which were aim of this study. A guidance model was developed for coverage decisions and guideline development in CDI. The model included pharmacotherapy with oral metronidazole or oral vancomycin, which is the mainstay for pharmacological treatment of CDI and is recommended by most treatment guidelines. RESULTS: A design for a patient-based cost-effectiveness model was developed, which can be used to estimate the cost-effectiveness of current and future treatment strategies in CDI. Patient-based outcomes were extrapolated to the population by including factors like, e.g., person-to-person transmission, isolation precautions and closing and cleaning wards of hospitals. CONCLUSION: The proposed framework for a population-based CDI model may be used for clinical and health economic assessments of CDI guidelines and coverage decisions for emerging treatments for CDI.

2.
Curr Opin Gastroenterol ; 30(1): 34-9, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24241245

RESUMO

PURPOSE OF REVIEW: To review the current evidence on fecal microbiota transplantations (FMTs) for recurrent Clostridium difficile infections (CDIs), metabolic syndrome and inflammatory bowel disease. RECENT FINDINGS: Recently, a randomized trial confirmed the efficacy of this treatment strategy in patients with recurrent CDI. For other disorders, evidence is still limited. To date, studies have been performed to try and influence the course of metabolic syndrome and inflammatory bowel disease. SUMMARY: There is increasing interest in the role of altered microbiota in the development of a myriad of diseases. Together with new insights comes an interest in influencing this altered microbiota as a potential target for therapy. FMTs are effective against recurrent CDI, a disorder caused by disruption of the normal microbiota. Restoration of intestinal flora and thereby restoration of colonization resistance is thought to be the mechanism responsible for cure. With the developments in FMT and the extension of this treatment modality to both intestinal and extra-intestinal diseases, a new field of targeted therapy awaits. The ultimate goal is the development of powerful probiotic regimens that can replace FMT. Currently, FMT should only be given in a strict experimental setting for other conditions than CDI.


Assuntos
Enterocolite Pseudomembranosa/terapia , Fezes/microbiologia , Microbiota , Transplante de Tecidos/métodos , Protocolos Clínicos , Seleção do Doador/métodos , Humanos , Doenças Inflamatórias Intestinais/terapia , Intestinos/microbiologia , Síndrome Metabólica/terapia , Recidiva , Transplante de Tecidos/efeitos adversos
3.
Ned Tijdschr Geneeskd ; 157(48): A6580, 2013.
Artigo em Holandês | MEDLINE | ID: mdl-24279951

RESUMO

Currently available broad spectrum antibiotics are not sufficiently effective against recurrent Clostridium difficile infections (CDI). Donor faecal microbiota transplantation is a very effective treatment for second and recurrent infection but is time-consuming and requires careful screening of donors. The new narrow spectrum antibiotic fidaxomicin is a good alternative in a first CDI or a first recurrence, but treatment is expensive and there are no data on its effectiveness in a second or later recurrence. Fidaxomicin is less effective against infections caused by the Ribotype 027 strain, a virulent strain that is regularly encountered in the Netherlands. The effectiveness of various other promising narrow spectrum antibiotics is currently being investigated. Medications that support the gut flora or the immune system seem to offer new perspectives. Expectations for the currently available probiotic preparations and toxin binders are not high.


Assuntos
Antibacterianos/uso terapêutico , Clostridioides difficile , Enterocolite Pseudomembranosa/tratamento farmacológico , Probióticos/uso terapêutico , Aminoglicosídeos/uso terapêutico , Clostridioides difficile/efeitos dos fármacos , Clostridioides difficile/patogenicidade , Infecções por Clostridium/tratamento farmacológico , Fezes/microbiologia , Fidaxomicina , Humanos , Países Baixos , Recidiva , Resultado do Tratamento
4.
N Engl J Med ; 368(5): 407-15, 2013 Jan 31.
Artigo em Inglês | MEDLINE | ID: mdl-23323867

RESUMO

BACKGROUND: Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high. We studied the effect of duodenal infusion of donor feces in patients with recurrent C. difficile infection. METHODS: We randomly assigned patients to receive one of three therapies: an initial vancomycin regimen (500 mg orally four times per day for 4 days), followed by bowel lavage and subsequent infusion of a solution of donor feces through a nasoduodenal tube; a standard vancomycin regimen (500 mg orally four times per day for 14 days); or a standard vancomycin regimen with bowel lavage. The primary end point was the resolution of diarrhea associated with C. difficile infection without relapse after 10 weeks. RESULTS: The study was stopped after an interim analysis. Of 16 patients in the infusion group, 13 (81%) had resolution of C. difficile-associated diarrhea after the first infusion. The 3 remaining patients received a second infusion with feces from a different donor, with resolution in 2 patients. Resolution of C. difficile infection occurred in 4 of 13 patients (31%) receiving vancomycin alone and in 3 of 13 patients (23%) receiving vancomycin with bowel lavage (P<0.001 for both comparisons with the infusion group). No significant differences in adverse events among the three study groups were observed except for mild diarrhea and abdominal cramping in the infusion group on the infusion day. After donor-feces infusion, patients showed increased fecal bacterial diversity, similar to that in healthy donors, with an increase in Bacteroidetes species and clostridium clusters IV and XIVa and a decrease in Proteobacteria species. CONCLUSIONS: The infusion of donor feces was significantly more effective for the treatment of recurrent C. difficile infection than the use of vancomycin. (Funded by the Netherlands Organization for Health Research and Development and the Netherlands Organization for Scientific Research; Netherlands Trial Register number, NTR1177.).


Assuntos
Antibacterianos/uso terapêutico , Clostridioides difficile , Diarreia/terapia , Fezes/microbiologia , Vancomicina/uso terapêutico , Administração Oral , Idoso , Terapia Combinada , Diarreia/tratamento farmacológico , Diarreia/microbiologia , Duodeno , Feminino , Humanos , Intubação Gastrointestinal , Masculino , Metagenoma , Pessoa de Meia-Idade , Recidiva , Irrigação Terapêutica
5.
Am J Hematol ; 87(5): 484-9, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22488175

RESUMO

Asplenic patients are at risk for pneumococcal sepsis. Patients with hyposplenic function, such as associated with sickle cell disease (SCD), are also at risk. However, tests to assess splenic function are either unavailable or lacking standardization. The aim of this study was to compare different methods for determining splenic function. Eighteen patients with SCD (i.e., 10 heterozygous (SC) and 8 homozygous (SS) SCD patients), and eight splenectomized patients were compared to 10 controls. All subjects underwent spleen scintigraphy, after which functional splenic volumes (FSV) were calculated. FSV was compared to immunological function and B cell-subsets, as well as phagocytic function represented by the presence of Howell Jolly bodies (HJB) and percentages of pitted red cells (PIT). Heterozygous SCD (SC) patients had increased splenic volumes, but diminished FSV, homozygous SCD (SS) patients were asplenic. Splenectomized and SS patients had a strongly reduced phagocytic and immunological function. SC patients had reduced anti-polysaccharide responses without an increase in PIT. FSV correlated significantly with phagocytic and immunological function. HJB were indicative of splenic dysfunction, HJB absence was not indicative of normal functioning splenic tissue. Although visualizing HJB is methodologically advantageous to PIT, both are valid biomarkers of splenic dysfunction. The amount of non-switched memory B cells is strongly correlated to FSV.


Assuntos
Baço/fisiopatologia , Esplenopatias/diagnóstico , Adulto , Idoso , Anemia Falciforme/fisiopatologia , Formação de Anticorpos , Antígenos/imunologia , Inclusões Eritrocíticas/ultraestrutura , Eritrócitos , Eritrócitos Anormais/ultraestrutura , Feminino , Humanos , Memória Imunológica , Subpopulações de Linfócitos/imunologia , Masculino , Pessoa de Meia-Idade , Tamanho do Órgão , Fagocitose , Cintilografia , Traço Falciforme/fisiopatologia , Pertecnetato Tc 99m de Sódio , Baço/diagnóstico por imagem , Baço/patologia , Esplenectomia/efeitos adversos , Esplenopatias/sangue , Esplenopatias/imunologia , Vacinação , Adulto Jovem
6.
Ned Tijdschr Geneeskd ; 155(47): A3788, 2011.
Artigo em Holandês | MEDLINE | ID: mdl-22129809

RESUMO

BACKGROUND: The Dutch Law on Medical Services ('Wet Geneeskundige Behandelingsovereenkomst') of 1995 declares that doctors must adhere to an Informed Refusal (a written Refusal of Medical Treatment) if the patient is unable to give informed consent on presentation at hospital. CASE DESCRIPTION: A comatose 81-year-old man was presented at the resuscitation area following attempted suicide with insulin. Treatment was suspended after the family presented the doctor with an Informed Refusal that had been signed by the patient. The question was to what extent this statement of intention or the family's wishes could prevail over the medical insight of the doctor. During subsequent discussion it became apparent that opinions vary greatly between doctors on this subject. CONCLUSION: Patients and doctors have little knowledge of negative statements of intention. The doctor can help the patient in formulating a realistic statement of intention, and document the patient's wishes in the patient's written or electronic medical dossier. A representative designated in writing can help to interpret the declaration of intention.


Assuntos
Coma/induzido quimicamente , Hipoglicemiantes/efeitos adversos , Insulina/efeitos adversos , Tentativa de Suicídio , Recusa do Paciente ao Tratamento , Idoso de 80 Anos ou mais , Tomada de Decisões , Humanos , Hipoglicemiantes/administração & dosagem , Insulina/administração & dosagem , Masculino , Países Baixos , Recusa do Paciente ao Tratamento/legislação & jurisprudência
7.
PLoS One ; 6(3): e17302, 2011 Mar 10.
Artigo em Inglês | MEDLINE | ID: mdl-21423748

RESUMO

BACKGROUND: Current management of asplenic patients is not in compliance with best practice standards, such as defined by the British Committee for Standards in Haematology. To improve quality of care, factors inhibiting best practice care delivery need to be identified first. With this study, we aimed to identify and quantify physicians' barriers to adhere to best practice management of asplenic patients in The Netherlands. METHODS AND PRINCIPAL FINDINGS: A cross-sectional survey, preceded by multiple focus group discussions, was performed among Dutch physicians responsible for prevention of infections in asplenic patients, including specialists (of Internal medicine and Surgery) and general practitioners (GPs). Forty seven GPs and seventy three hospital specialists returned the questionnaire, yielding response rates of 47% and 36.5% respectively. Physicians reported several barriers to deliver best practice. For both GPs and specialists, the most frequently listed barriers were: poor patient knowledge (>80% of hospital specialists and GPs) and lack of clarity about which physician is responsible for the management of asplenic patients (50% of Internists, 46% of Surgeons, 55% of GPs). Both GPs and hospital specialists expressed to experience a lack of mutual trust: specialists were uncertain whether the GP would follow their advice given on patient discharge (33-59%), whereas half of GPs was not convinced that specialists' discharge letters contained the correct recommendations. Almost all physicians (>90%) indicated that availability of a national guideline would improve adherence to best practice, especially if accessible online. CONCLUSION: This study showed that, in accordance with reports on international performance, care delivery for asplenic patients in The Netherlands is suboptimal. We identified and quantified perceived barriers by physicians that prevent adherence to post-splenectomy guidelines for the first time. Better transmural collaboration and better informed patients are likely to improve the quality of care of the asplenic patient population. A national, online-available guideline is urgently required.


Assuntos
Médicos/estatística & dados numéricos , Padrões de Prática Médica/estatística & dados numéricos , Baço , Atitude do Pessoal de Saúde , Estudos Transversais , Fidelidade a Diretrizes , Conhecimentos, Atitudes e Prática em Saúde , Diretrizes para o Planejamento em Saúde , Humanos , Medicina Interna , Inquéritos e Questionários
8.
J Hosp Med ; 5(8): 466-70, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20578047

RESUMO

BACKGROUND: After splenectomy, patients are at increased risk of sepsis with considerable mortality. This risk can be reduced by taking preventive measures, such as prescribing immunizations and antibiotic prophylaxis. Studies from various countries show that a substantial percentage of patients are not managed adequately. The aim of the present study was to investigate the quality of care in the prevention of infections after splenectomy in Dutch hospitals. The research questions were two-fold: (1) Is there an association between hospital teaching status and guideline adherent preventive measures? (2) Which factors contribute to hospital performance? METHODS: A total of 28 Dutch hospitals (30%) participated in the study. A retrospective review of medical records of 536 splenectomy patients was performed. Adherence to prevention guidelines was assessed for all patients, and analyzed according to teaching status and the presence or absence of a post-splenectomy protocol. RESULTS: (1) University hospitals in the Netherlands offered higher quality of care than other teaching and nonteaching hospitals. There were only small differences between nonuniversity teaching and nonteaching hospitals. (2) The presence of a hospital post-splenectomy protocol did not improve vaccination rates. Other aspects of practice organization, such as surgical staff size and keeping a complication registry were only weakly related to performance. CONCLUSIONS: In the Netherlands, university hospitals deliver state-of-the-art care in the prevention of infections in asplenic patients more often than nonuniversity teaching and nonteaching hospitals. The availability of a hospital protocol does not seem to contribute to guideline adherence.


Assuntos
Hospitais , Assistência ao Paciente/normas , Esplenectomia/reabilitação , Humanos , Imunização/normas , Auditoria Médica , Países Baixos , Estudos Retrospectivos , Choque Séptico/prevenção & controle
9.
Clin Infect Dis ; 48(11): 1559-65, 2009 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-19392637

RESUMO

BACKGROUND: The long-term prognosis of endocarditis is described primarily in relation to clinical outcome measures-for example, such complications as cerebrovascular accident, cardiac failure, need for cardiac surgery, relapse rate, and mortality. To our knowledge, to date, no studies have examined the health-related quality of life and the prevalence of long-term persistence of physical symptoms for survivors of left-sided native valve endocarditis. METHODS: We conducted a prospective follow-up study of patients treated for left-sided native valve endocarditis from 1 November 2000 through 31 October 2003 in 23 hospitals in the Netherlands. Of 86 patients eligible to participate, 55 completed questionnaires administered 3 m and 12 m after discharge; an additional 12 patients completed questionnaires 12 m after discharge only, making a total of 67 patients in our study. Persistence of symptoms and employment status were recorded. The health-related quality of life was measured by using the Dutch version of the Medical Outcomes Study Short Form 36-item health survey and the Posttraumatic Stress Disorder questionnaire. RESULTS: Three months after the end of antimicrobial treatment, 41 (75%) of 55 patients still had physical symptoms. Twelve months after the end of antimicrobial treatment, 36 (54%) of 67 patients still had physical symptoms. Before the episode of endocarditis, 30 (81%) of 37 patients aged < or =60 years were employed and working. At 3 m follow-up, 16 (52%) of 31 patients returned to work, and at 12 m follow-up, 24 (65%) of 37 patients were working. One year after discharge, the health-related quality of life was impaired in 5 of 8 dimensions, compared with age-adjusted standard values, and 7 (11%) of 64 patients suffered from posttraumatic stress disorder. CONCLUSIONS: A year after discharge, most survivors of left-sided native valve endocarditis still had persisting symptoms and a seriously diminished quality of life, and 11% of patients suffered from posttraumatic stress disorder.


Assuntos
Endocardite Bacteriana/complicações , Avaliação de Resultados em Cuidados de Saúde , Qualidade de Vida/psicologia , Transtornos de Estresse Pós-Traumáticos/epidemiologia , Adulto , Idoso , Feminino , Seguimentos , Nível de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Países Baixos/epidemiologia , Estudos Prospectivos , Inquéritos e Questionários , Sobreviventes , Resultado do Tratamento
11.
Arch Intern Med ; 168(3): 302-7, 2008 Feb 11.
Artigo em Inglês | MEDLINE | ID: mdl-18268172

RESUMO

BACKGROUND: The clinical course of left-sided native valve infective endocarditis varies from uncomplicated disease to fulminant infection. Although several factors are known to affect clinical outcome, it is difficult to predict morbidity and mortality in individual patients. The objective of this study was to determine the value of serial C-reactive protein (CRP) measurements as a predictor of clinical outcome. METHODS: One hundred twenty-three consecutive patients who fulfilled the Duke criteria for definite left-sided native valve infective endocarditis were prospectively enrolled. Poor outcome was defined as serious infectious complications or death. Patients were followed up for 12 weeks after the end of antimicrobial therapy. Multivariate analysis was used to examine the relative importance of the CRP level as a predictor of poor outcome after adjusting for age, abscess, multivalvular involvement, and Staphylococcus aureus infection. RESULTS: After 1 week of therapy, the adjusted odds ratio for poor outcome was 10.3 (95% confidence interval, 2.2-49.4) for patients with CRP levels in the highest tertile (>122 mg/L [to convert to nanomoles per liter, multiply by 9.524]) vs the lowest tertile (1-69 mg/L). A low percentage decline during the first week of treatment was statistically significantly associated with a higher risk of poor outcome (logistic regression coefficient, 1.1; P = .009). At no point in time did CRP level predict the need for cardiac surgery. CONCLUSION: High CRP level after 1 week of treatment and a slow percentage decline in CRP level during the first week of treatment are indicators of poor clinical outcome.


Assuntos
Anti-Infecciosos/uso terapêutico , Proteína C-Reativa/análise , Endocardite Bacteriana/sangue , Doenças das Valvas Cardíacas/sangue , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/análise , Endocardite Bacteriana/diagnóstico , Endocardite Bacteriana/mortalidade , Feminino , Doenças das Valvas Cardíacas/microbiologia , Doenças das Valvas Cardíacas/mortalidade , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prognóstico , Estudos Prospectivos , Resultado do Tratamento
12.
FEMS Immunol Med Microbiol ; 49(2): 224-34, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17328756

RESUMO

Ixodes ricinus ticks and mice can be infected with both Borrelia burgdorferi sensu stricto and Borrelia garinii. The effect of coinfection with these two Borrelia species on the development of murine Lyme borreliosis is unknown. Therefore, we investigated whether coinfection with the nonarthritogenic B. garinii strain PBi and the arthritogenic B. burgdorferi sensu stricto strain B31 alters murine Lyme borreliosis. Mice simultaneously infected with PBi and B31 showed significantly more paw swelling and arthritis, long-standing spirochetemia, and higher numbers of B31 spirochetes than did mice infected with B31 alone. However, the number of PBi spirochetes was significantly lower in coinfected mice than in mice infected with PBi alone. In conclusion, simultaneous infection with B. garinii and B. burgdorferi sensu stricto results in more severe Lyme borreliosis. Moreover, we suggest that competition of the two Borrelia species within the reservoir host could have led to preferential maintenance, and a rising prevalence, of B. burgdorferi sensu stricto in European I. ricinus populations.


Assuntos
Grupo Borrelia Burgdorferi , Borrelia burgdorferi , Doença de Lyme/microbiologia , Animais , Artrite Infecciosa/microbiologia , Bacteriemia , Contagem de Colônia Microbiana , DNA Bacteriano/sangue , Modelos Animais de Doenças , Edema , Extremidade Inferior , Doença de Lyme/imunologia , Doença de Lyme/patologia , Doença de Lyme/fisiopatologia , Camundongos , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BL , Reação em Cadeia da Polimerase
13.
Chest ; 130(4): 1165-72, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17035452

RESUMO

STUDY OBJECTIVES: The long-term outcomes of patients with community-acquired pneumonia (CAP) in terms of symptom resolution and health-related quality of life (HRQL) is unknown. Our objective was to determine the rate of symptom resolution using validated patient-based outcome measures, and to assess HRQL 18 months after the episode. PARTICIPANTS: Patients were recruited from a group enrolled in a randomized trial comparing two durations of treatment for CAP. Between 2000 and 2003, we included 102 adults with a mild-to-moderate-severe CAP (pneumonia severity index, < or = 110). INTERVENTIONS: CAP-related symptoms were assessed until month 18 using the CAP score. The CAP score was divided into respiratory and well-being sections to assess the recovery of respiratory and well-being symptoms separately. The HRQL was assessed at 18 months using the Medical Outcomes Study 36-item short form (SF-36) questionnaire and compared to a Dutch reference group. RESULTS: Respiratory symptoms resolved within 14 days, while the well-being symptoms resolved more slowly. Taking the prepneumonia status into account, patients recovered fully from pneumonia after 6 months. Patients with comorbid conditions had significantly more symptoms prepneumonia and during follow-up than patients without comorbidities, but at all time points the proportion of patients that reached > or = 80% of the prepneumonia health level did not depend on comorbidity, age, or etiology. SF-36 scores at 18 months were significantly impaired in four of the eight dimensions for patients with comorbid illness, but did not differ from the reference population for patients without comorbid illness. CONCLUSION: Patients with mild-to-moderate-severe CAP recover fully from pneumonia after 6 months. The presence of symptoms beyond 28 days and any impairment in HRQL were found to reflect age and comorbidity rather than the persistent effects of the pneumonia itself.


Assuntos
Amoxicilina/administração & dosagem , Antibacterianos/administração & dosagem , Infecções Comunitárias Adquiridas/tratamento farmacológico , Convalescença , Pneumonia Bacteriana/tratamento farmacológico , Pneumonia Pneumocócica/tratamento farmacológico , Qualidade de Vida , Idoso , Infecções Comunitárias Adquiridas/diagnóstico , Infecções Comunitárias Adquiridas/psicologia , Convalescença/psicologia , Método Duplo-Cego , Esquema de Medicação , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde , Pneumonia Bacteriana/diagnóstico , Pneumonia Bacteriana/psicologia , Pneumonia Pneumocócica/diagnóstico , Pneumonia Pneumocócica/psicologia , Qualidade de Vida/psicologia , Índice de Gravidade de Doença
14.
BMJ ; 332(7554): 1355, 2006 Jun 10.
Artigo em Inglês | MEDLINE | ID: mdl-16763247

RESUMO

OBJECTIVE: To compare the effectiveness of discontinuing treatment with amoxicillin after three days or eight days in adults admitted to hospital with mild to moderate-severe community acquired pneumonia who substantially improved after an initial three days' treatment. DESIGN: Randomised, double blind, placebo controlled non-inferiority trial. SETTING: Nine secondary and tertiary care hospitals in the Netherlands. PARTICIPANTS: Adults with mild to moderate-severe community acquired pneumonia (pneumonia severity index score < or = 110). INTERVENTIONS: Patients who had substantially improved after three days' treatment with intravenous amoxicillin were randomly assigned to oral amoxicillin (n = 63) or placebo (n = 56) three times daily for five days. MAIN OUTCOME MEASURES: The primary outcome measure was the clinical success rate at day 10. Secondary outcome measures were the clinical success rate at day 28, symptom resolution, radiological success rates at days 10 and 28, and adverse events. RESULTS: Baseline characteristics were comparable, with the exception of symptom severity, which was worse in the three day treatment group. In the three day and eight day treatment groups the clinical success rate at day 10 was 93% for both (difference 0.1%, 95% confidence interval--9% to 10%) and at day 28 was 90% compared with 88% (difference 2.0%,--9% to 15%). Both groups had similar resolution of symptoms. Radiological success rates were 86% compared with 83% at day 10 (difference 3%,--10% to 16%) and 86% compared with 79% at day 28 (difference 6%,--7% to 20%). Six patients (11%) in the placebo group and 13 patients (21%) in the active treatment group reported adverse events (P = 0.1). CONCLUSIONS: Discontinuing amoxicillin treatment after three days is not inferior to discontinuing it after eight days in adults admitted to hospital with mild to moderate-severe community acquired pneumonia who substantially improved after an initial three days' treatment.


Assuntos
Amoxicilina/administração & dosagem , Antibacterianos/administração & dosagem , Pneumonia Bacteriana/tratamento farmacológico , Administração Oral , Adulto , Idoso , Infecções Comunitárias Adquiridas/tratamento farmacológico , Método Duplo-Cego , Esquema de Medicação , Feminino , Hospitalização , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Países Baixos , Resultado do Tratamento
15.
Clin Immunol ; 116(2): 174-81, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15993364

RESUMO

Lipopolysaccharide (LPS) binding protein (LBP) facilitates the transfer of LPS of Gram-negative bacteria to the pattern recognition receptor CD14, resulting in activation of immunocompetent cells. LBP can also facilitate the binding of lipoarabinomannan, a major cell wall component of mycobacteria, to immune cells. To determine the role of LBP in the immune response to pulmonary Mycobacterium tuberculosis infection, LBP gene-deficient (-/-) and normal wild-type (WT) mice were intranasally infected with M. tuberculosis. LBP-/- mice displayed a similar survival and mycobacterial outgrowth in lungs and liver, although they demonstrated a reduced lymphocyte recruitment and activation during the early stages of infection. The clearance of pulmonary infection with the non-pathogenic M. smegmatis was also unaltered in LBP-/- mice. These data suggest that LBP does not contribute to an effective host response in M. tuberculosis infection.


Assuntos
Proteínas de Fase Aguda/imunologia , Proteínas de Transporte/imunologia , Glicoproteínas de Membrana/imunologia , Tuberculose Pulmonar/imunologia , Proteínas de Fase Aguda/deficiência , Proteínas de Fase Aguda/genética , Animais , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , Proteínas de Transporte/genética , Contagem de Células , Quimiocinas/metabolismo , Citocinas/metabolismo , Feminino , Granulócitos/patologia , Fígado/microbiologia , Pulmão/metabolismo , Pulmão/microbiologia , Pulmão/patologia , Ativação Linfocitária/imunologia , Linfócitos/patologia , Macrófagos/patologia , Glicoproteínas de Membrana/deficiência , Glicoproteínas de Membrana/genética , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Infecções por Mycobacterium não Tuberculosas/imunologia , Infecções por Mycobacterium não Tuberculosas/microbiologia , Mycobacterium smegmatis/imunologia , Análise de Sobrevida , Tuberculose Pulmonar/microbiologia , Tuberculose Pulmonar/patologia
16.
Clin Infect Dis ; 40(10): 1404-10, 2005 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-15844061

RESUMO

BACKGROUND: On surgical wards, body temperature is routinely measured, but there is no proof that this is useful for detecting postoperative infection. The aim of this study was to compare temperature measurements (the test) with the confirmed absence or presence of a postoperative infection (the reference standard). METHODS: A prospective triple-blinded diagnostic study involving 308 consecutive patients was performed. A positive test result was defined as a postoperative temperature > or = 38.0 degrees C. The reference standard was considered to indicate a postoperative infection if results of a bacterial culture were positive or if an infection was suspected on clinical grounds. RESULTS: Data for 284 of 308 patients were analyzed (2282 temperature measurements). The prevalence of infection was 7% (19 of 284 patients). The temperature curves of patients were used as units of analysis and revealed that a temperature > or = 38.0 degrees C had a sensitivity of 37% (95% confidence interval [CI], 0.16%-0.62%) and a specificity of 80% (95% CI, 0.75%-0.85%). The likelihood ratio for a positive test result was 1.8 (95% CI, 0.7-4.0) and for a negative test result was 0.8 (95% CI, 0.4-1.4). When all 2282 measurements were considered as independent test results, the positive predictive value was only 8% (95% CI, 5%-13%). Six of 8 patients with a severe infection had temperatures < 38 degrees C. CONCLUSION: Routine measurement of body temperature is of limited value in the detection of infection after elective surgery for noninfectious conditions. Serious postoperative infections can even occur without an accompanying increase in temperature.


Assuntos
Infecções Bacterianas/diagnóstico , Temperatura Corporal , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Valor Preditivo dos Testes , Sensibilidade e Especificidade
17.
Shock ; 22(6): 543-7, 2004 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-15545826

RESUMO

Platelet-activating factor (PAF), a glycerophospholipid with proinflammatory properties, exerts its biological effects by interacting with the PAF receptor (PAFR) expressed on many different cell types. The PAFR specifically binds phosphorylcholine, the biologically active component of PAF. However, phosphorylcholine is also a component of the cell wall of nontypeable Haemophilus influenzae (NTHi). In recently published in vitro experiments, the invasion of respiratory epithelial cells by NTHi was mediated by the PAFR. To determine the role of the PAFR in host defense against pneumonia induced by NTHi, PAFR-deficient (PAFR-/-) and normal wild-type mice were intranasally inoculated with NTHi. The absence of a functional PAFR was associated with a normal innate immune response as indicated by similar bacterial counts, myeloperoxidase activity, and inflammation within the pulmonary compartment of PAFR-/- and wild-type mice. These data indicate that the PAFR does not interfere with the clearance of NTHi from the respiratory tract.


Assuntos
Infecções por Haemophilus/microbiologia , Haemophilus influenzae/imunologia , Glicoproteínas da Membrana de Plaquetas/deficiência , Receptores Acoplados a Proteínas G/deficiência , Sistema Respiratório/microbiologia , Animais , Quimiocina CXCL2 , Quimiocinas/análise , Quimiocinas/metabolismo , Citocinas/metabolismo , Modelos Animais de Doenças , Feminino , Haemophilus influenzae/crescimento & desenvolvimento , Haemophilus influenzae/isolamento & purificação , Pulmão/enzimologia , Pulmão/microbiologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Peroxidase/metabolismo , Glicoproteínas da Membrana de Plaquetas/genética , Receptores Acoplados a Proteínas G/genética , Sistema Respiratório/enzimologia
18.
Int Immunol ; 16(11): 1605-11, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15452020

RESUMO

LPS-binding protein (LBP) can facilitate the transfer of cell wall components of both Gram-negative bacteria (LPS) and Gram-positive bacteria (lipoteichoic acid) to inflammatory cells. Although LBP is predominantly produced in the liver, recent studies have indicated that this protein is also synthesized locally in the lung by epithelial cells. To determine the role of LBP in the immune response to pneumonia, LBP gene-deficient (-/-) and normal wild-type (WT) mice were intra-nasally infected with either Streptococcus pneumoniae or Klebsiella pneumoniae, common Gram-positive and Gram-negative pathogens, respectively. Pneumococcal pneumonia was associated with a 7-fold rise in LBP concentrations in bronchoalveolar lavage fluid of WT mice; LBP-/- mice infected with S. pneumoniae showed a similar survival and a similar bacterial burden in their lungs 48 h post-infection. In Klebsiella pneumonia, however, LBP-/- mice demonstrated a diminished survival together with an enhanced bacterial outgrowth in their lungs. These data suggest that LBP is important for a protective immune response in Klebsiella pneumonia, but does not contribute to an effective host response in pneumococcal pneumonia.


Assuntos
Proteínas de Fase Aguda/imunologia , Proteínas de Transporte/imunologia , Infecções por Klebsiella/imunologia , Klebsiella pneumoniae/imunologia , Glicoproteínas de Membrana/imunologia , Pneumonia Pneumocócica/imunologia , Streptococcus pneumoniae/imunologia , Proteínas de Fase Aguda/genética , Animais , Proteínas de Transporte/genética , Infecções por Klebsiella/mortalidade , Infecções por Klebsiella/patologia , Lipopolissacarídeos/imunologia , Glicoproteínas de Membrana/genética , Camundongos , Camundongos Knockout , Pneumonia Pneumocócica/mortalidade , Pneumonia Pneumocócica/patologia , Ácidos Teicoicos/imunologia
19.
J Infect Dis ; 189(4): 711-6, 2004 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-14767826

RESUMO

Platelet-activating factor (PAF) is a phospholipid with proinflammatory properties that binds to a specific receptor (PAF receptor [PAFR]) that is expressed on many different cell types. PAFR is able to bind phosphorylcholine, which is present in both PAF and the pneumococcal cell wall. Activation of respiratory epithelial cells in vitro results in up-regulation of PAFR, which, in turn, facilitates invasion of Streptococcus pneumoniae. To determine the role of PAFR in host defense against pneumococcal pneumonia, PAFR-deficient (PAFR(-/-)) and wild-type (wt) mice were inoculated intranasally with S. pneumoniae. PAFR(-/-) mice were relatively resistant to pneumococcal pneumonia, as indicated by delayed and reduced mortality, diminished outgrowth of pneumococci in lungs, and reduced dissemination of the infection (all P<.05, vs. wt mice). PAFR(-/-) mice also had less pulmonary inflammation. These data provide evidence that PAFR is used by S. pneumoniae to induce lethal pneumonia.


Assuntos
Glicoproteínas da Membrana de Plaquetas/deficiência , Glicoproteínas da Membrana de Plaquetas/fisiologia , Pneumonia Pneumocócica/imunologia , Receptores Acoplados a Proteínas G/deficiência , Receptores Acoplados a Proteínas G/fisiologia , Animais , Cruzamentos Genéticos , Modelos Animais de Doenças , Feminino , Inflamação , Contagem de Leucócitos , Pulmão/microbiologia , Pulmão/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Glicoproteínas da Membrana de Plaquetas/genética , Pneumonia Pneumocócica/patologia , Receptores Acoplados a Proteínas G/genética , Streptococcus pneumoniae/isolamento & purificação , Sobrevida , Fatores de Tempo
20.
Int Immunol ; 16(3): 509-16, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-14978024

RESUMO

Toll-like receptors (TLR) play an essential role in the innate recognition of microorganisms by the host. To determine the role of TLR4 in host defense against lung tuberculosis, TLR4 mutant (C3H/HeJ) and wild-type (C3H/HeN) mice were intranasally infected with live Mycobacterium tuberculosis. TLR4 mutant mice were more susceptible to pulmonary tuberculosis, as indicated by a reduced survival and an enhanced mycobacterial outgrowth. Lung infiltrates were more profound in TLR4 mutant mice and contained more activated T cells. Splenocytes of infected TLR4 mutant mice demonstrated a reduced capacity to produce the protective type 1 cytokine IFN-gamma upon antigen-specific stimulation, indicating that TLR4 may be involved in the generation of acquired T cell-mediated immunity. These data suggest that TLR4 plays a protective role in host defense against lung infection by M. tuberculosis.


Assuntos
Glicoproteínas de Membrana/fisiologia , Receptores de Superfície Celular/fisiologia , Tuberculose Pulmonar/imunologia , Animais , Hipersensibilidade Tardia/imunologia , Hipersensibilidade Tardia/metabolismo , Interferon gama/imunologia , Interferon gama/metabolismo , Interleucina-4/imunologia , Interleucina-4/metabolismo , Pulmão/metabolismo , Pulmão/microbiologia , Pulmão/patologia , Macrófagos/imunologia , Macrófagos/metabolismo , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Camundongos , Camundongos Mutantes , Mycobacterium tuberculosis/imunologia , Mycobacterium tuberculosis/metabolismo , Receptores de Superfície Celular/genética , Receptores de Superfície Celular/metabolismo , Baço/imunologia , Baço/metabolismo , Subpopulações de Linfócitos T/imunologia , Subpopulações de Linfócitos T/metabolismo , Receptor 4 Toll-Like , Receptores Toll-Like , Tuberculose Pulmonar/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...